Go back

UK medicines regulator to ‘further streamline’ clinical trials

MHRA went from being “reactive passenger” to “suddenly becoming a driver” during pandemic, says CEO

The chief executive of the UK’s medicines regulator has announced plans to “further streamline and remove barriers” to clinical trials in the wake of Covid-19 to make it “an enabling regulator from now on”.

Speaking at the SV Health Investors Forum on 30 November, June Raine said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) would soon be consulting on changes to clinical trial legislation to replace EU rules.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.